Home / Health / Novo Nordisk Cuts Prices on Wegovy and Ozempic by 30% in the US
Novo Nordisk Cuts Prices on Wegovy and Ozempic by 30% in the US
18 Nov
Summary
- Novo Nordisk reduces cash price of Wegovy and Ozempic by 30% to $349 per month
- Price cut aims to improve affordability and accessibility of these medications
- Novo Nordisk expanding coverage and working to lower costs for patients
On November 18, 2025, the Danish pharmaceutical company Novo Nordisk announced a significant price reduction for its popular weight-loss drug Wegovy and diabetes medication Ozempic in the United States. Effective immediately, the new monthly cash price for either of these GLP-1 drugs will be $349, down from the previous $499.
Novo Nordisk's executive vice president, Dave Moore, stated that the company is committed to ensuring "real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them." The price cut is part of a broader strategy to expand access, including building relationships with telehealth providers, major retailers, and working with the administration to lower costs for patients living with chronic diseases like obesity and type 2 diabetes.
The previous cash price for Wegovy had matched that of a full dose of Zepbound, a competing drug from Eli Lilly. With the new pricing, Novo Nordisk aims to provide immediate cost savings for those without insurance coverage or who choose to self-pay for these medications.
